LILRB4 and acute myeloid leukemia: Furthermore, in acute myeloid leukemia (AML), FTO inhibition can lead to downregulation of leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), render AML cells vulnerable to activated T cells, and simultaneously overcome hypomethylating agent (HMA)-induced immune evasion.